Lexicon Pharmaceuticals Inc (LX31)
XMUN 
NASDAQ (CM) Primary XMUN Summary
LX31 Chart
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Lexicon Pharmaceuticals Inc (LX31) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lexicon Pharmaceuticals Inc ever had a stock split?
Lexicon Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Michael S. Exton CEO | XMUN Exchange | US5288723027 ISIN |
| US Country | 103 Employees | - Last Dividend | 21 May 2015 Last Split | 7 Apr 2000 IPO Date |
Overview
Lexicon Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative pharmaceutical products. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals has emerged as a leader in its field, primarily focusing on orally-delivered small molecule drug candidates. The company has established strategic collaboration and license agreements with industry giants such as Bristol-Myers Squibb Company and Genentech, Inc., which facilitate the advancement of its research and development efforts in creating life-changing therapies for patients worldwide.
Products and Services
- Sotagliflozin
An orally-delivered small molecule drug that has successfully completed Phase III clinical trials, Sotagliflozin is at the forefront of Lexicon Pharmaceuticals' promising pipeline. This innovative drug candidate is primarily targeted for the treatment of heart failure and type 1 diabetes, offering a new hope for patients suffering from these chronic conditions through its novel mechanism of action and potential benefits.
- LX9211
Currently in Phase II clinical development, LX9211 represents another key component of the company's robust portfolio. Designed to address the crippling effects of neuropathic pain, LX9211 aims to alleviate suffering and improve the quality of life for patients battling this challenging condition. Its progression into Phase II trials underscores Lexicon Pharmaceuticals' commitment to targeting and treating complex pain syndromes with cutting-edge science and therapeutics.
- LX2761
A promising candidate in the early stages of clinical development, LX2761 is in Phase I trials with a focus on the treatment of issues affecting the gastrointestinal tract. This drug exemplifies Lexicon Pharmaceuticals' strategic exploration into novel therapeutic areas, leveraging its expertise in small molecule drug development to potentially offer new solutions for digestive health complications.
